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Abstract
Background: Dengue virus (DENV) infection is the most common arthropod-borne viral disease in man and there
are approximately 100 million infections annually. Despite the global burden of DENV infections many important
questions regarding DENV pathogenesis remain unaddressed due to the lack of appropriate animal models of
infection and disease. A major problem is the fact that no non-human species naturally develop disease similar to
human dengue fever (DF) or dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Apart from
other risk factors for severe dengue such as host genetics and secondary infection with a heterologous DENV, virus
virulence is a risk factor that is not well characterized.
Results: Three clinical DENV-1 isolates from Cambodian patients experiencing the various forms of dengue disease
(DF, DHF, and DSS) were inoculated in BALB/c mice at three different concentrations. The DENV-1 isolates had
different organ and cell tropism and replication kinetics. The DENV-1 isolate from a DSS patient infected the largest
number of mice and was primarily neurotropic. In contrast, the DENV-1 isolates from milder clinical dengue cases
infected predominantly lungs and liver, and to a lesser extent brain. In addition, infection with the DENV isolate
derived from a DSS patient persisted for more than two weeks in a majority of mice compared to the other DENV-
1 isolates that peaked during the first week.
Conclusions: These results confirm the in vitro findings of the same DENV-1 isolates, that showed that the isolate
derived from a DSS patient can be distinguished based on phenotypic characteristics that differ from the isolates
derived from a DF and DHF case [1]. We observed in this study that the DSS virus isolate persist longer in vivo with
extensive neuroinvasion in contrast to the other DENV-1 isolates originating in milder human cases. Genomic
characterization of the three clinical isolates identified six amino acid substitutions unique for the DSS isolates that
were located both in structural genes (M and E) and in non-structural genes (NS1, NS3, and NS5). The
characterization of these clinically distinct DENV-1 isolates highlight that DENVs within the same genotype may
have different in vivo phenotypes.
Highlights: ￿ Clinical DENV-1 isolates have different organ tropism in BALB/c mice.
￿ The isolate from a DSS patient is primarily neurotropic compared to the other isolates.
￿ The DENV-1 isolates have different in vivo replication kinetics.
￿ The isolate from a DSS patient persists longer compared to the other isolates.
￿ These phenotypic differences confirm our earlier in vitro findings with the same DENV-1 isolates. Thus, DENVs
within the same serotype and genotype may differ enough to affect clinical conditions in vivo.
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Background
The dengue viruses (DENV) belong to the genus flavi-
virus of the Flaviviridae family, and consist of four (1-4)
antigenically related, but clearly distinct viruses (sero-
types). The DENV particle is enveloped, and has a sin-
gle-stranded positive-sense RNA genome of
approximately 11 kb that resembles a messenger RNA
w i t hac a po nt h e5 ’ e n db u tn op o l y ( A )t a i la tt h e3 ’
end. The RNA genome encodes a 3411 long precursor
polyprotein that contains three structural proteins (C,
prM, and E), and seven nonstructural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The open
reading frame is flanked by two nontranslated regions
(5’ and 3’ NTR) of approximately 95-135 and 114-650
nucleotides, respectively, that have characteristic second-
ary structures that are required for efficient translation
and replication [2,3].
The DENVs are endemic in tropical and subtropical
areas and more than one hundred million people get
infected annually. Infection can be either asymptomatic,
or cause an acute febrile illness that is characterized by
fever, headache, retro-orbital pain, arthralgia, and myal-
gia. This condition can progress into dengue haemor-
rhagic fever (DHF), with cardinal signs such as
increased vascular permeability, thrombocytopenia, focal
or generalized haemorrhages. DF may progress into the
life-threatening state of dengue shock syndrome (DSS)
[4]. In the recent WHO guidelines, for case manage-
ment purposes, DHF and DSS cases are now grouped
together as “severe dengue” (group C) [5].
Uncontrolled urbanization and globalization have
resulted in the geographic spread of the DENV-trans-
mitting mosquitoes Aedes aegypti and A. albopictus,c o -
circulation of different DENV serotypes, and increased
frequency of dengue epidemics [6]. There has been a
severe increase of DHF/DSS in many endemic regions,
emphasizing the urgent need of an effective vaccine.
Despite the global burden of DENV infections many
important questions regarding DENV pathogenesis
remain unaddressed due to the lack of appropriate ani-
mal models of infection and disease. A major problem is
the fact that no non-human species naturally develop
disease similar to human DF or DHF/DSS. Epidemiolo-
gical, clinical, and laboratory findings indicate that both
genetic differences in the virus and the host immune
response contribute to the occurrence and severity of
disease [7].
In the search for better animal models for dengue,
several approaches to investigate infection of DENV in
mouse have been proposed. One of two major strategies
have been to modulate the mouse to render it more sus-
ceptible to DENV infection, e.g. SCID mice transplanted
with cultured, DENV-susceptible tumour cells [8-10].
The other major alternative has been to modify the
DENV in order to make it more infection-competent in
the murine host, e.g. mouse-neuroadapted DENV
[11-14], or virus serially passaged in mouse [15,16]. The
relevance of these models to human pathogenesis
remains unknown.
The immunocompetent BALB/c mouse is susceptible
t oD E N Vi n f e c t i o na n dh a sb e e nu s e de x t e n s i v e l yt o
study various aspects of DENV infection pathogenesis,
despite the lack of clinical symptoms [17-20]. Mouse-
adapted DENV strains increase the susceptibility to
DENV infection and elicit clinical symptoms in BALB/c
mice [11,21]. The relevance of these observations to
infection with wild-type DENV strains, however, should
be interpreted with caution due to the altered genotype
and phenotype of the passaged virus.
We have previously reported that DENV-1 isolates
only passaged once in C6/36 cells (passage 1), derived
from patients presenting the clinically distinct forms of
dengue (DF, DHF, and DSS), can be distinguished in
vitro based on different replication kinetics in mamma-
lian Vero cells and apoptosis in C6/36. The DSS-derived
isolate (accession number: FJ639694) had a unique phe-
notype compared to the DF- and DHF-derived isolates
(accession numbers: HQ624983 and HQ624984, respec-
tively) and genomic comparison revealed six amino acid
substitutions unique for the DSS isolate that were
located in the structural viral M and E genes that con-
stitute the extracellular mature virus particle, and in the
NS1, NS3, and NS5 genes. The E protein mediates host
cell receptor binding, viral entry, and is a major target
for humoral immunity [22,23]. The role of NS1 in virus
replication is not known, but is thought to be involved
in facilitation of viral infection and in the pathogenesis
of DENV infection [24,25]. The NS3 acts together with
its cofactor NS2B as the viral serine protease needed for
DENV precursor polyprotein-processing [3,26-28]. The
NS5 protein has a dual enzymatic activity with an RNA
dependent RNA polymerase activity in its C-terminal
domain, and a methyltransferase activity at its N-term-
inal end. Hence, these six mutations could ultimately
affect antibody response, host immune pathways, and
virus replication.
The primary aim of the present study was to investi-
gate whether there is a phenotype difference in vivo
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findings, by studying difference in infectivity in BALB/c
mice and to investigate the cell and organ tropism. The
second aim was to determine if the inoculated virus
concentration and the effects of the infection correlated,
primarily by measuring the levels of inflammatory cyto-
kines induced by the infection.
Results
DENV infection and Organ Tropism
All mice had detectable levels of DENV specific IgG
antibodies at day 15 post-infection (p.i.), confirming the
intravenous route to be appropriate choice in order to
successfully infect all mice. In total 54.3% of the DENV-
1 infected mice had detectable levels of viral RNA;
48.2% of the mice infected with the DF isolate; 55.6% of
the DHF isolate infected mice; and 59.3% of the DSS
isolate infected mice (table 1). All mice survived the
infection without presenting any clinical signs but
pathological lesions such as haemorrhage could be
detected, most notably in brain, liver, lung tissue, and to
some extent in spleen.
Haemorrhage in lungs was most pronounced in the
DF-infected mice, whereas the DHF-infected mice
experienced haemorrhage in lungs, liver and to some
extent in brain. The DSS isolate seemed to have some
neurotropism as the DSS-infected mice had extensive
bleedings in the brain, whereas the peripheral organs
showed only minor signs of haemorrhage. None of the
NC mice exhibited any clinical signs or tissue pathology.
The three DENV-1 isolates showed different tropism;
the two DENVs obtained from a DF and DHF case
infected primarily lungs, spleen, and liver, whereas the
DENV from a DSS patient infected lungs, spleen, and
exhibited a strong tropism for brain tissue (p = 0.001).
The results are summarized in table 1. The effects of
infection in lung tissue showed a positive correlation to
inoculated virus concentration and time-point, with a
peak of infection at day 6 p.i. (p = 0.003) combined with
the highest titer 1.5 × 10
6 PFU/mL in the inoclum (p<
0.001) (table 2).
Risk of Infection and Kinetics of Infection
The DENV-1 isolates exhibited different risks for infec-
tion that depended both on virus concentration in the
inoculum (p = 0.012) and on time-point p.i. (p = 0.014)
(Figure 1). The effects of inoculated dose of infectious
virus showed a positive correlation to the total number
of infected mice for each virus isolate, and infection
peaked on day 6 p.i. for all three viruses.
Kinetics of infection differed between the three
DENV-1 isolates. Viral RNA in the DF and DHF inocu-
lated mice was predominantly detected during the first
week of infection, and declined during the second week.
Six inoculated mice tested positive after inoculation
with the DF, and DHF isolates, respectively, both on day
3 and 6 p.i. During the second week (day 15 p.i.), how-
ever, only 1 and 3 mice tested positive after inoculation
with the DF- and DHF-viruses, respectively. The time-
course of infection differed in the DSS- infected mice
that showed a delayed response to inoculation compared
to the DF- and DHF-infected mice. Day 3 p.i. had the
lowest number of DSS-infected mice (3 positive mice)
whereas at day 6 p.i. 7 mice were infected, and 6 during
Table 1 Viral RNA was found in various organs depending on inoculated DENV-1 isolate (DF, DHF, or DSS), virus
concentration in inoculum, and time-point p.i. In total 54.3% of the DENV-1 infected mice had detectable levels of
viral RNA
DENV isolate DF DHF DSS
Titer (PFU/mL)* 1.5 × 10
4 1.5 × 10
5 1.5 × 10
6 1.5 × 10
4 1.5 × 10
5 1.5 × 10
6 1.5 × 10
4 1.5 × 10
5 1.5 × 10
6
Day (p.i.)** 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15
Heart - - - - - - - - - - - - - - - - - - - - - - - - - - -
Lungs - - - 2 3 - 2 3 1 - - - - 2 - 2 2 1 - - - - 3 1 1 1 1
Spleen 1 - - - - - 2 - - 1 - - - - 2 2 1 - - 1 - - 1 1 2 - -
Brain - - - - - - 1 - - 1 1 - - - - - 3 - - 1 2 1 3 2 - 2 -
Liver - - - - - - - - - - - - 1 1 - 2 - - - - - - - - - - -
Kidneys - - - - - - - - - - - - - - - - - - - 1 - - - - - - -
Infected mice 1 - - 2 3 - 3 3 1 2 1 - 1 2 2 3 3 1 - 3 2 1 3 3 2 2 1
Infected mice per titer 1 5 7 3 5 7 4 7 5
Infected mice per day p.i. 6 6 1 6 6 3 3 7 6
Σ infected mice per virus isolate 13 15 16
% infected mice per virus isolate 48.2% 55.6% 59.3%
* Titer of inoculum was significant (p = 0.012).
** Time-point post-infection was significant (p = 0.014).
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number of mice infected with the DF and DHF isolates
peaked during day 3 and 6 p.i. in contrast to the num-
ber of DSS-infected mice that peaked during day 6 and
15 p.i (Figure 2).
Overall, the DSS isolate replicated in a majority of
infected mice and for a longer period of time compared
to the DENVs obtained from milder cases (Figure 2).
Cytokine secretion in serum
IFNg levels peaked during the first week of infection and
most notably on day 3 p.i. that showed the highest levels
of IFNg (p = 0.007). There was also a positive
correlation to inoculated virus dose where the highest
titer (1.5 × 10
6 PFU/mL) elicited the strongest IFNg
response (p = 0.002). A positive titer dependent correla-
tion to IL-6 levels was observed in all three groups of
DENV-1 inoculated mice (p = 0.028) (data not shown).
There was a time and virus dependent difference regard-
ing detected IL-10 levels. The DF-inoculated mice had
higher levels of IL-10 compared to the DHF- and DSS-
inoculated mice (p = 0.007), with a peak at day 3 p.i (p
=0 . 0 0 9 ) (Figure 3). The DF-inoculated mice also domi-
nated in serum levels of secreted MCP-1 and showed
the biggest difference compared to the DSS-inoculated
mice (p < 0.0001), followed by DHF-inoculated mice (p
=0 . 0 1 1 ) (Figure 4). MCP-1 levels peaked at day 3 p.i.
whereupon it decreased (p=<0 . 0 0 1 ). Inoculated virus
titer showed a positive correlation to measured serum
levels of RANTES in all DENV-1 inoculated mice (p=
0.0036), and DF-inoculated mice dominated (p = 0.048).
IL-13 and RANTES showed a dose-dependent response
to inoculated virus. IL-1b, IL-2, and TNFa did not show
any statistically significant relationships to any of the
analysed parameters (table 3).
Discussion
DENV infections are a major public health problem and
constitute a real challenge due to the absence of vac-
cines and effective antiviral drugs. There are no non-
Table 2 Risk of infection in lungs
Inoculated virus
(PFU/mL)
Risk of infection
1.5 × 10
4 0
1.5 × 10
5 0.41
1.5 × 10
6 0.52
Days p.i. Risk of infection
3 0.26
6 0.52
15 0.15
Both inoculated DENV-1 concentration and time-point were significant (p<
0.001 and p = 0.003, respectively). The risk for infection in the lungs with the
DF isolate was highest on day 6 p.i. and showed a positive correlation to
inoculated virus.
Figure 1 Estimated risk of infection depending on virus concentration, day p.i. and virus isolate.
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DENV inoculation into peripheral sites and that resem-
ble the clinical symptoms observed in humans [29]. The
mechanisms underlying the immune responses to
DENV infection are still poorly defined, and the lack of
suitable animal models has hampered investigation of
host- and virus-specific mechanisms that control pri-
mary and sequential DENV infections.
In this study, we have compared three minimally pas-
saged DENV-1 isolates from patients experiencing the
various clinical forms of dengue disease (DF; DHF; and
DSS, respectively) in vivo by infection in mouse. We
show that the isolate from a DSS patient infected the
largest number of BALB/c mice, with a different tropism
compared to the DENV-1 isolates obtained from milder
clinical cases during the same outbreak. This indicates
that DENVs within the same serotype and genotype
may differ enough to cause various clinical conditions in
vivo. These results confirm a phenotypic distinction pre-
viously observed in vitro with the same DENV-1 isolates
where the DSS isolate replicated less efficiently in mam-
malian Vero cells than the DF and DHF isolates, and
elicited apoptosis in mosquito C6/36 cells [1].
T h ea i mo ft h es t u d yw a st oc o m p a r ew i l d - t y p ef e a -
tures of DENV-1 isolates passaged only once in vitro
and never before inoculated in mouse or cultured in
mouse cells prior to direct intravenous inoculation into
BALB/c mice. BALB/c mice are known to be susceptible
for DENV infection although with discrete pathological
features [11,30]. We found that the mice did not
develop dengue disease, and did not present any symp-
toms of the infection. However, viral RNA was detected
Figure 2 Persistence of infection shown as the number of mice
infected out of the total mice inoculated, independent of
inoculated virus concentration. Nine mice per DENV isolate and
time-point in total were inoculated with the corresponding DENV
isolates; DF, DHF, and DSS, respectively.
Figure 3 Box plots showing median IL-10 (solid line) by DENV-
1 isolates independent of inoculated virus concentration and
days p.i. The line in the middle of each box represents the median;
the boxes consists of 1
st and 3
rd quartile, whiskers are 1.5*(3
rd
quartile-1
st quartile). Outliers are marked with an open circle. The
DF-inoculated mice had higher levels of IL-10 compared to the
DHF- and DSS-inoculated mice (p = 0.007), with a peak at day 3 p.i
(p = 0.009).
Figure 4 Box plots showing median MCP-1 (solid line) by
DENV-1 isolates independent of inoculated virus concentration
and days p.i. The line in the middle of each box represents the
median; the boxes consists of 1
st and 3
rd quartile, whiskers are 1.5*
(3
rd quartile-1
st quartile). Outliers are marked with an open circle.
The DF-inoculated mice had the highest serum levels of secreted
MCP-1 and showed the biggest difference compared to the DSS-
inoculated mice (p < 0.0001), followed by DHF-inoculated mice (p=
0.011). MCP-1 levels peaked at day 3 p.i. and whereupon it
decreased (p = < 0.001).
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injected (table 1). We were unable to detect any sys-
temic viremia and this suggests an absence or a very
low level of virus replication in circulating peripheral
blood mononuclear cells. Alternatively, the lack of
detectable viraemia could indicate that the virus had
already disseminated into peripheral sites, since tissue
infection was measured from day 3 p.i.
In brief, viral RNA was detected by qRT-PCR in spleen,
liver, lungs, kidneys, and brain. Viral RNA was found in
the kidneys in only one mouse, which is in line with ear-
lier studies [31]. Organ tropism clearly differed between
the three clinical DENV-1 isolates and our findings sug-
gest that the disease severity may correlate with high tis-
s u ev i r a lb u r d e n ,e v e ni fp l a s m av i r a e m i aw a sb e l o wt h e
detection limit. The DENV isolate from a DSS case
showed a strong preference for brain tissue, compared to
the two isolates from milder dengue cases that primarily
were found in other organs as lungs and liver. Neuro-
tropism in mice has been previously suggested to be
associated with DENV virulence when comparing
DENV-3 isolated from Brazilian patients [32].
Breakdown of the blood-brain barrier in DENV
infected mice have been described before, and were
shown to be dose-dependent [33]. Genomic sequencing
performed previously [1] identified a unique amino acid
substitution L®F476 in the E protein of the DSS isolate
compared to the DF and DHF isolates, that may explain
the neurotropic character of the DSS-isolate. The NS1
gene of the DSS isolate harboured another unique
amino acid substitution, K®R115 in comparison to the
two other DENV-1 isolates. The soluble form of NS1
(sNS1) is a dominant target of humoral immunity and
activates complement components in normal human
serum, and is proposed to play a significant role in the
pathogenesis of disease [25,34]. The NS1 glycoprotein is
glycosylated at two sites, N130 and N270, and glycosyla-
tion of both residues has been suggested to be required
for neurovirulence in mice [35]. It is remains to be elu-
cidated whether the possible breakdown of the blood-
brain barrier and neurotropic character of the DSS iso-
late has any correlation to the disruption of the
endothelium observed in humans suffering from vascu-
lar leakage. The three remaining amino acid substitu-
tions unique for the DSS isolate were located in the NS
protein 3 (S®P118), and 5 (T®I49, and S®N830).
These differences could potentially alter the enzymatic
activity of these proteins.
The DSS isolate seemed to persist longer in vivo since
viral RNA was detected in a majority of mice on day 15
p.i. compared to the DF and DHF infected mice, and
thereby exhibited infection kinetics differing from the
two other DENV-1 isolates (DF and DHF) where viral
RNA decreased after day 6 p.i. Thus, the DSS isolate
could be regarded as more virulent than the two other
DENV-1 strains, since a majority of the DSS-inoculated
mice had detectable levels of viral RNA, infection was
also less affected by the dose of inoculums and persisted
longer in a majority of mice (Figure 1). The wild-type
DENVs analyzed here could provide evidence for differ-
ences in virus replication, which in turn could influence
the clinical outcomes of the infection, and eventually
partitally explain some differences in virulence observed
in humans.
These results confirm the in vitro findings of the same
DENV-1 isolates, that showed that the strains derived
from a DSS patient can be distinguished based on phe-
notypic characteristics from the isolates derived from a
DF and DHF case [1]. We have previously shown that
the DSS virus isolate exhibit much slower replication
kinetics in mammalian Vero cells and an apoptotic
Table 3 Serum cytokine levels in mice inoculated with
DENV-1 isolates from patients with DF, DHF, and DSS,
respectively, and independent of inoculated virus
concentration
Day p.i. Cytokine DF DHF DSS Mock
3 IFNg 3.10 3.24 2.08 0.09
IL-1b 3.15 0.00 0.00 0.00
IL-2 1.46 2.00 1.05 0.00
IL-6 1.48 1.65 2.69 3.22
IL-10 4.20 3.13 0.00 0.00
IL-13 88.83 73.12 80.23 98.84
MCP-1 71.58 34.25 21.45 0.00
RANTES 35.11 13.17 15.93 9.76
TNFa 6.44 3.97 3.78 0.00
6 IFNg 2.53 1.65 1.92 0.00
IL-1b 3.15 0.00 0.00 0.00
IL-2 1.46 1.44 2.21 2.21
IL-6 0.36 0.77 3.10 2.69
IL-10 2.05 0.00 0.00 0.00
IL-13 70.84 62.33 51.19 121.60
MCP-1 22.12 14.54 3.37 0.00
RANTES 20.47 14.16 24.46 10.43
TNFa 2.45 2.15 0.00 0.00
15 IFNg 1.24 1.28 1.70 0.87
IL-1b 0.00 0.00 0.00 0.00
IL-2 2.20 1.19 5.61 0.00
IL-6 0.18 1.88 1.65 0.03
IL-10 1.03 0.00 0.00 0.00
IL-13 67.20 91.70 84.96 75.57
MCP-1 21.53 14.54 3.37 0.00
RANTES 27.68 17.22 20.75 15.02
TNFa 1.73 0.00 1.48 0.00
The cytokines were measured in pg/mL.
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study that the DSS virus isolate persist longer in vivo
with extensive neuroinvasion.
Cytokines involved in inflammation were quantified in
serum collected from inoculated mice and compared in
regard to DENV-1 isolate, virus titer inoculated, and
time-point p.i. Overall, the levels of the proinflammatory
cytokines (IFNg,I L - 1 b, IL-2, IL-6, IL-10, IL-13, MCP-1,
RANTES, and TNFa) quantified were low, which is
most probably due to fact that BALB/c mice is poorly
s u s c e p t i b l et ow i l d - t y p eD E N V s .T h em i c ed i dn o t
develop clinical apparent disease, and showed only dis-
crete lesions in internal organs. Common for several
cytokines, however, was a dose-dependent response to
inoculated virus (IFNg, IL-6, IL-13, and RANTES). The
highest levels of measured cytokines were also in general
at the beginning of the experimental period (IFNg,I L -
1 0 ,a n dM C P - 1p e a k e da td a y3p . i . ) .Ac u r i o u sf i n d i n g
was that DF-inoculated mice had higher detectable
serum levels of IL-10, MCP-1, and RANTES, which
have been seen to be increased in patients with severe
DHF and DSS [36-42]. The preference for the brain of
the DHF-, and most notably the DSS-infected mice,
could imply locally high levels of proinflammatory cyto-
kines that do not circulate systemically. This could
explain why the IL-10, MCP-1, and RANTES levels
dominated in the DF-inoculated mice, since the thoracic
and abdominal organs were the primary target for DF
isolate. Cytokines like IL-1b,I L - 2 ,a n dT N F a did not
show any differences compared to mock-infected con-
trols and this could be due to the transient nature of
many cytokines as well as the limited susceptibility of
DENVs in mice.
Conclusions
We have previously shown in vitro that the isolate from
a DSS case could be distinguished based on replication
kinetics and apoptosis from isolates originating in
milder cases. In this study we have extended the charac-
terization of those clinical DENV-1 isolates derived
from patients exhibiting the various forms of dengue ill-
ness. Despite their close relatedness, the DENV-1 isolate
from a DSS case was phenotypically different from the
other two isolates by significant brain invasiveness and a
higher infectivity in BALB/c mice. The isolates from a
DF and DHF case infected primarily lungs and liver, and
to a limited extent brain and infection declined faster
after day 6 p.i than in DSS-infected mice.
This is the first time different clinical South-East
Asian DENV isolates have been directly compared for
the in vivo characteristics in BALB/c mice. To define
key elements involved in the virulence of these charac-
terized DENV-1 phenotypes reverse genetics systems are
needed. Additional low-passage strains of the different
DENV serotypes of each clinical forms of dengue are
required to fully decipher the complex mechanisms gov-
erning DENV pathogenesis.
Materials and methods
Virus
Three dengue serotype-1 (DENV-1) virus strains isolated
from patient sera during a DENV outbreak in the Kam-
pong Cham province, Eastern Cambodia, in 2007, were
used. The isolates were obtained from patients experien-
cing the three distinct clinical forms of dengue disease:
DF, DHF and DSS, according to the WHO classification
[43]. Patient information regarding the analysed clinical
DENV isolates is presented in previous work by Tuisku-
nen, A. et al., 2011. Blood samples were collected
between day 2 and 6 after onset of disease and the sero-
types were determined at the Institute Pasteur in Cam-
bodia (IPC) by nested reverse transcriptase-polymerase
chain reaction, according to Lanciotti procedure modi-
fied by Reynes et al. [44]. The virus isolates were
obtained during the DENFRAME study, which has been
approved by the Cambodian National Ethics Committee
and patient’s enrolment was subject to obtaining a writ-
ten consent signed by the patients, or the under 16 year
old patient’s legal representatives.
Each DENV was isolated in A. albopictus mosquito
cell line C6/36 (CRL 1660, ATCC), and thereafter pro-
pagated by one passage. The C6/36 cells were main-
tained in Leibovitz-15 medium, supplemented with 2%
tryptose phosphate broth, and 5% fetal calf serum (Invi-
trogen, Stockholm, Sweden) and maintained at 28°C for
6 days. Cell culture supernatant was centrifuged for 10
min at 15000 rpm, titrated as previously described [1]
and stored at -80°C in a solution of sucrose [1.5 M] and
hepes [1 M]. Virus had not undergone any previous pas-
sage in mouse.
Animals
The animal experimental procedures were approved by
the Committee for Laboratory Animal Science of the
Swedish Board of Agriculture (ethical permit ID no:
339/07).
Female BALB/c mice (Nova, Sollentuna, Sweden) age
6 weeks weighing 20 g were maintained on a standard
laboratory diet with water ad libitum and housed under
specific pathogen-free conditions at the animal facility
of the Swedish Institute for Communicable Disease
Control (SMI) in Stockholm, Sweden. Mice subjected to
the same treatment were kept in groups of 4-5 mice per
cage and handled according to the international guide-
lines for experimentation on animals. DENV-1 infected
mice were housed in a biological safety level (BSL) 3
isolator, and negative control mice were housed in a
BSL 2 facility.
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T h e r ew e r e9 9m i c ei nt o t a ld i v i d e di n t of o u rg r o u p s
with 27 mice each according to the 3 DENV-1 isolates
and 18 mock infected negative controls (NC). Each
group of 27 mice were subdivided into three groups of
nine mice that were injected intravenously (i.v.) in the
t a i lv e i nw i t has i n g l ed o s e( 1 . 5×1 0
4 PFU/mL; 1.5 ×
10
5 PFU/mL; or 1.5 × 10
6 PFU/mL, respectively) of
infective DENV-1 without adjuvant. Similarly, the NC
group of 18 mice received 150 uL of Leibovitz-15 med-
ium supplemented with sucrose [1.5 M] and hepes [1
M] (table 4). The mice were monitored daily for clinical
signs.
Blood that was obtained via a cardiac puncture of
mice immediately after euthanasia by 4.5 - 4.8% isoflur-
ane gas inhalation on day 3; 6, and 15 p.i. All mice were
immediately splenectomised after euthanasia and there-
after stored at -80°C.
Detection of DENV RNA in BALB/c mice
To assess viral burden in tissues of infected mice, organs
such as liver, heart, spleen, lungs, brain, and kidneys
were harvested, weighed, and homogenized using Stain-
less Steel Beads (5.0 mm diameter) with a TissueLyser
apparatus (Qiagen, Hilden, Germany). Total RNA from
tissues was extracted immediately after dissection using
the RNeasy Mini kit according to the manufacturer’s
instructions (Qiagen).
Mouse sera were obtained by centrifugation of whole
blood for 3 minutes at 2000 g in microtainer EDTA
tubes (Becton, Dickinson and Company, Temse, Bel-
gium). Viral RNA from thawed aliquots of serum (140
uL) was extracted using QIAamp Viral RNA Mini kit
(Qiagen). RNA samples, eluted in RNAse-free water,
were stored at -80°C. Quantitative measurements of
total viral RNA were performed as previously described
[45].
IFA for virus-specific antibody detection
An in-house immunofluorescence assay (IFA) was used
as previously described [46] essentially to verify that all
DENV-1 infected mice had raised a DENV specific anti-
body response.
Cytokine dosage
Cytokine levels in mouse sera collected from all inocu-
lated mice, including mock infected, were measured as
duplicates with Milliplex Mouse Cytokine/Chemokine
Panel (Millipore) in a Luminex 100 (Luminex, Bio-Rad,
Sweden). The following cytokines and chemokines were
analysed according to the manufacturer’s instructions:
IFNg,I L - 1 b, IL-2, IL-6, IL-10, IL-13, MCP-1, RANTES,
and TNFa.
Statistical Analysis
To test the effect of virus, titer and days p.i. on the risk
of DENV infection in mouse organs binomial regression
with a log link was used. Parametric bootstrap with
10.000 replicates was drawn from an assumed binomial
probability model. The effect of virus, titer and day
between smaller and larger models were then evaluated
by comparing the deviance, extracted from the repli-
cates. The largest model, within each analysis of the
infection risk in an organ, included the main effects
virus, titer and day plus the interactions virus by titer,
virus by day and titer by day.
Median regression was used to evaluate the relation-
ship between virus isolate, day, and titer on the different
cytokines. As most cytokines displayed highly right
skewed distributions in some virus isolates the use of
median estimates yielded more robust results than with
the use of mean based methods. Day and titer were ana-
lyzed separately with two main models per cytokine:
Cytokine = group + day + group by day interaction; and
Cytokine = group + titer + group by titer interaction. P-
values < 0.05 were used as statistically significant results.
All analyses and graphs were performed using the statis-
tical software R (version 2.13.1, 2011).
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